Synedgen is a brand that specializes in cutting-edge technology for the treatment of gastrointestinal (GI) diseases. They have developed a groundbreaking platform called the Multivalent Innate Immune Signaling Target (MIIST), which aims to repair and regenerate mucosal and dermal barriers in the body. By promoting barrier repair, MIIST305 effectively manages secondary immune signaling, preventing inflammation, infection, and injury.

One of the unique aspects of Synedgen's approach is their glycopolymer discovery process. This process carefully selects targets that have been conserved throughout millions of years of evolution, allowing for the design of target-specific therapeutics that are highly effective in treating GI diseases. Synedgen's innovative technology has been supported by a broad US and international patent estate, ensuring their continued ability to develop new chemical entities and future therapeutics.

With a focus on healing, limiting infection, and controlling inflammation, Synedgen's MIIST therapeutics offer hope for patients suffering from GI diseases